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Abstract — Chronic alcohol consumption is a major cause of liver cirrhosis which, however, develops in only a minority of heavy drin-
kers. Evidence from twin studies indicates that genetic factors account for at least 50% of individual susceptibility. The contribution of
genetic factors to the development of diseases may be investigated either by means of animal experiments, through linkage studies in
families of affected patients, or population based case–control studies. With regard to the latter, single nucleotide polymorphisms of
genes involved in the degradation of alcohol, antioxidant defense, necroinflammation, and formation and degradation of extracellular
matrix are attractive candidates for studying genotype–phenotype associations. However, many associations in early studies were found
to be spurious and could not be confirmed in stringently designed investigations. Therefore, future genotype–phenotype studies in
alcoholic liver disease should meet certain requirements in order to avoid pure chance observations due to a lack of power, false
functional interpretation, and insufficient statistical evaluation.
INTRODUCTION
Alcoholic liver disease (ALD) accounts for >50% of all
chronic liver diseases in industrialized countries and is
responsible for >50 000 annual deaths due to cirrhosis and
associated complications (Corrao et al., 1997; Kim et al.,
2002; John and Hanke 2002).
ALD comprises various degrees of liver injury due to direct
and indirect effects of continuous exposure towards toxic
amounts of alcohol, including alcoholic fatty liver, alcoholic
steatohepatitis, as well as alcohol-induced hepatic fibrosis
and cirrhosis, either with or without inflammation (Ishak
et al., 1991). Moreover, chronic alcohol consumption is an
established risk factor for the development of hepatocellular
carcinoma in patients with liver cirrhosis (Stickel et al., 2002;
Morgan et al., 2004). While nearly all heavy drinkers reveal
fatty liver, 10–35% of alcoholics are diagnosed with alcoholic
hepatitis, and 10–20% develop cirrhosis (Teli et al., 1995).
Hence, only a minority of heavy drinkers develop severe liver
disease. The cause for this variable susceptibility towards
alcohol is yet unclear.
As with other chronic liver diseases, an alcoholic
individual’s risk to develop ALD is governed by a complex
interplay of numerous genes with several known or unknown
environmental factors. For example, it is well established
that the amount of alcohol consumed is highly correlated
with evolution of cirrhosis (Bellentani et al., 1997). In
addition, alcoholics with chronic hepatitis C virus infection
or obesity display more severe liver damage (Wiley et al.,
1998; Raynard et al., 2002). However, these factors are not
sufficient to explain the wide diversity of hepatic damage
suggesting a role of certain host factors. Accordingly, female
gender and the presence of the hemochromatosis gene
mutation were identified to increase the likelihood of
alcohol-related hepatic damage. Evidence has accumulated
supporting the concept that genetic factors unrelated to gender
contribute to the emergence of ALD (Hrubec and Omenn,
1981). For example, twin studies have shown that the
concordance for alcoholic cirrhosis is significantly greater in
monozygotic than in dizygotic twins, leading to the conclusion
that 50% of the phenotypic variation of alcoholism can
be attributed to genetic modifiers (Reed et al., 1996). The
identification of these factors would improve our understand-
ing of the pathophysiology of ALD and greatly help managing
affected patients. Identification of genetic factors indicative of
rapid disease progression would augment preventive strategies
and the timing of therapeutic interventions including liver
transplantation. Identified genetic risk factors may also play
a role in the progression to cirrhosis in other chronic liver
diseases as it represents a common end point of many chronic
liver diseases.
METHODOLOGY AND ANALYSIS OF
GENETIC STUDIES
While some diseases, such as cystic fibrosis, alpha-1
antitrypsin deficiency, and phenylketonuria, are related to
mutations of single gene loci inherited according to Mendelian
rules, ALD and the majority of other liver disease are
polygenic and represent ‘complex traits’. Considerable efforts
are required to determine the role of a single or a group of
genes, since their effects on disease manifestation are usually
smaller than crucial gene defects in monogenic disorders.
Genetically modified animals may be useful in the analysis
of disease-specific gene loci either through using knockout
mice deficient for the gene of interest, or conversely,
transgenic mice which overexpress genes that are relevant
for the manifestation or progression of certain diseases
(Hillebrandt et al., 2003). Recently, an elegant technique
termed ‘quantitative trait loci’ (QTL) analysis has been
introduced which combines molecular biology tools with
classical approaches of genetics to search for genetic
determinants which so far had not been linked to a disease’s
pathogenesis (Darvasi, 1998; Korstanje et al., 2002). In QTL
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analysis, all crossbred animals in an experiment are both
phenotyped with regard to a certain quantitative marker and
genotyped through a ‘genome-wide scan’ for markers with
known localization within the genome. Using this technique,
Hillebrandt et al. (2002) have described a susceptibility locus
on chromosome 15 that significantly affects the stage of
fibrosis in fibrosis-susceptible BALB/c mice. Excitingly, the
same group later confirmed their findings by showing that
the corresponding gene in humans which codes for comple-
ment factor 5, is in fact a quantitative trait gene that modifies
liver fibrosis in patients with chronic hepatitis C (Hillebrandt
et al., 2005).
The detection of disease-modulating genes in humans is
more difficult and challenging. Currently, three different
approaches have been applied: family-based linkage analyses,
candidate gene association studies, and genome-wide
polymorphism studies. It is beyond the scope of this review
to describe family-based linkage and genome-wide scanning
analyses and to dissect their advantages and disadvantages in
detail, and therefore, readers are referred to concise review
articles focused on this issue (Tabor et al., 2002; Day, 2003).
Here, emphasis will be exclusively put on genotype–
phenotype associations studies.
In humans, candidate gene case–control studies investiga-
ting associations between single nucleotide polymorphisms
(SNPs) and certain disease end-points have been the most
extensively applied method (Hirschhorn et al., 2002). In this
kind of study, the frequency of one or several polymorphisms
are compared between a group of patients displaying the
phenotype of interest and another group of unaffected controls
exposed to the same insult, e.g. alcohol or viral hepatitis
(Gambaro et al., 2000; Day, 2003). An association with the
disease is assumed should there be a significantly higher
frequency of one allele or genotype in either of the groups.
Genotype–phenotype studies most commonly focus on the
role of SNPs. In an SNP, a single base is substituted for
another one thereby leading to an altered base triplet that
potentially could code for a different amino acid when located
in the coding sequence. In effect, this could result in an altered
function of the generated protein. Also, some SNPs result
in altered quantitative transcription of the respective gene
if located in the promoter sequence. However, most
polymorphisms are situated in non-coding regions of genes
and, therefore, have little or no impact. This has to be taken
into account, when choosing polymorphisms for association
studies. SNPs are the most common type of allelic variation
and can be found throughout the human genome at a frequency
of 1 every 1000–2000 bp (http://www.ncbi.nlm.nih.gov/SNP).
So far nearly three million of them are described. Genotyping
of SNPs is possible through electrophoresis-based techniques,
such as restriction fragment length polymorphism (RFLP)
analysis in which a restriction enzyme cuts a PCR product
at the site of the SNP thereby generating DNA fragments of
different sizes which are then made visible by agarose gel
electrophoresis. Since only a proportion of SNPs can be
detected through RFLP, PCR techniques using sequence-
specific primer pairs that solely amplify the corresponding
wild-type or mutated DNA template have been established.
Other experimental tools are more complex and include
oligonucleotide ligation assays, single-strand conformational
polymorphism analysis, or DNA sequencing. While all these
techniques are appropriate for small-scale studies on single
or a limited number of SNPs, high-throughput genotyping
platforms are required to study larger cohorts and multiple
SNPs such as in silico mapping (Wang and Rannala, 2005),
fluorescent dye-based genotyping (Wilson et al., 1990),
DNA microarrays (Lau et al., 2005), and mass spectrometry
technologies (Younossi et al., 2005).
The selection of a candidate gene for an association case–
control study is usually based on biological plausibility in
chosen genes that play a putative role in the pathogenesis of
the studied disease (Day, 2003). With regard to ALD, it is impor-
tant to separate genes that are related to alcoholism from those
that affect progression of liver disease. In addition, some genes
are known to be mutated in a hereditary type of the disease
and, therefore, become an interesting candidate for a case–
control study that investigates the sporadic type of the disorder.
As mentioned above, genes that were identified through research
with knockout or transgenic animals are ideal candidates to be
further studied in human cohorts. Novel candidate genes can
also be identified through DNA microarrays, and then screened
for in larger cohorts of affected individuals. After a gene has
been selected to serve as a candidate, it should be clarified
whether SNPs with a functional implication reside in the corre-
sponding gene. Only genetic variants that result in altered tran-
scription, RNA stability, or protein function are likely to
modulate disease progression (Daly, 2003). So, the functional
implications of a SNP or a haplotype (a cluster of gene loci
that co-segregate) should be characterized through in vitro and
in vivo evidence prior to their testing in association studies.
An important task in genotype–phenotype association
studies in ALD is the selection of appropriate cases and
controls matched for potential modifiers of liver damage.
Therefore, a suitable recruitment strategy should control for
potential confounders of an association such as age and
gender, extent of alcohol exposure, co-morbidities and co-
medication, and ethnicity. These attempts should be made in
order to avoid a confounding effect by population stratifi-
cation due to a marked variation of the allele frequency of
certain genes among subgroups with a different baseline risk
for the disease (Cardon and Palmer, 2003). Both cases and
controls need to be well characterized, and subjects with a
similar alcohol consumption and a near normal histology on
liver biopsy represent ideal controls. Obviously, this is a
difficult task in many instances, so alternatively, controls
should at least have normal liver-specific laboratory results
and a normal appearance of some type of liver imaging,
e.g. ultrasound (Day, 2003).
Statistical issues have become increasingly complex in
genetic studies and, particularly, statistical power is important
since it reflects the probability that a statistically significant
effect is demonstrated when it really exists. Currently, a power
of 0.8 is generally accepted for genetic association studies
which translates into a 80% chance of detecting a true
association (Bataller et al., 2003). In ‘underpowered’ studies,
both a type I and a type II error may occur. Type I errors refer
to false-positive associations frequently seen in studies with a
low sample size, whereas type II errors represent false-
negative findings that may result from insufficient patient
characterization or population stratification. Recently, a
sample size of >150 has been defined as a critical threshold
for the replication validity of genetic association studies
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(Ioannidis et al., 2001). So, a power calculation prior to patient
recruitment based on the known allele frequency should
become an integral part of the planning of any candidate
gene association study.
For data analysis, adequate statistical means have to be
applied that adjust for all potential co-factors of the disease.
In studies with small sample sizes, a Fisher’s exact test is
appropriate, whereas larger sets of data require the application
of a c2-test. Most well-analyzed genetic case–control studies
performed a multivariate logistic regression analysis which
allows for correction of quantitative and qualitative covariates
as predictors of the disease outcome. If all these prerequisites
are taken into account, large numbers of patients and controls
are usually necessary to give a study a sufficient power to
detect a significant effect (Cardon and Bell, 2001). This
highlights the need for networking in the scientific commun-
ity and calls for cooperation among different research centers.
PATHOGENESIS OF ALCOHOLIC LIVER DISEASE:
POSSIBLE CANDIDATE GENES
Alcohol is hepatotoxic through a variety of mechanisms which
lead to acute and chronic tissue injury, and possibly, to
cirrhosis. With regard to the liver, alcohol-induced tissue
damage is primarily based on the toxicity of its first metabolite
acetaldehyde. In addition, the increased formation of reactive
oxygen species (ROS), such as hydrogen peroxide (H2O2)
and superoxide anions (O–2) have been implicated as a cause
of liver injury in various forms of chronic liver diseases
including ALD (Parola and Robino, 2001). Increased ROS
formation is mainly caused by the induction of CYP2E1.
The elevated generation of ROS produces cytotoxic oxidative
stress and increased lipid peroxidation through the formation
of 4-hydroxy 2,3-nonenal (HNE), 4-hydroxy-2,3-alkenals
(HAKs) and malondialdehyde (MDA). The capacity of
CYP2E1 to oxidize ethanol is increased up to 10-fold in heavy
consumers which consecutively increases the pro-oxidative
burden (Kessova and Cederbaum, 2003). Defense mechanisms
such as antioxidant mitochondrial and cytosolic enzymes can
offset some of the toxicity derived from oxidative stress but
may become saturated as it persists, or downregulated as liver
damage progresses. Furthermore, excessive alcohol consump-
tion can lead to an increased portosystemic uptake of
gut-derived endotoxins from gastrointestinal bacteria which
contribute to necroinflammation in alcoholic hepatitis by acti-
vating Kupffer cells through the CD14/toll-like receptor-4
complex to produce ROS via NADPH oxidase (Parlesak
et al., 2000; Wheeler et al., 2001).
The uniform morphologic response of liver tissue to
repeated injury from various sources, including alcohol, is
fibrosis which closely resembles the process of scar forming
(Bataller and Brenner, 2005). As a response to triggers such
as acetaldehyde, ROS, lipid peroxides, and endotoxins, liver
macrophages (Kupffer cells) and other inflammatory cells
become activated to produce a battery of growth factors and
cytokines including the powerful mitogen platelet-derived
growth factor (PDGF) and the most important profibrogenic
cytokine transforming growth factor b1 (TGFb1) which
stimulate hepatic stellate cells (HSC) and portal fibroblasts
(Fig. 1). The transformation of quiescent HSC rich in vitamin
A into an activated myofibroblast (MFB)-like phenotype rich
in a-smooth muscle actin and devoid of vitamin A is
considered the central event in the pathophysiology of liver
fibrosis (Bataller and Brenner, 2001). Activated HSCs/MFBs
markedly increase the production of extracellular matrix
Fig. 1. Alcohol, acetaldehyde, or prooxidants trigger the activation of HSC/myofibroblasts either directly or indirectly through the release of cytokines (IL-1,
IL-6, TGF-b1, PDGF). HSC/MFB acquire a profibrogenic phenotype and the ability to migrate, contract, and synthesize ECM. In acute (alcoholic) liver damage,
matrix synthesis and degradation is balanced due to concomitant upregulation of matrix-degrading enzymes (MMPs). In chronic liver damage, net matrix
accumulation occurs because MMPs are downregulated as a result of upregulated TIMP-1 and TIMP-2 activity.
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(ECM) molecules which comprise collagens, non-collagenous
glycoproteins, proteoglykans, and glycosaminoglykans. How-
ever, the accumulation of fibrous material does not simply
result from increased production of ECM, but also from its
impaired degradation which plays an equally important role
(Schuppan et al., 2001). In normal liver tissue, a subtle balance
is maintained between matrix synthesis and degradation. The
latter is exerted by a group of matrixmetalloproteinases
(MMPs) released by various liver cells. MMPs process a wide
range of ECM substrates (Benyon and Arthur, 2001) and their
activity is regulated by a group of specific inhibitors produced
by activated HSCs/MFBs termed tissue inhibitors of matrix-
metalloproteinases (TIMPs). Upregulation of TIMP-1 and
TIMP-2 is responsible for the loss of MMP expression during
fibrogenesis in the liver (Herbst et al., 1997).
All phases in the development of ALD are regulated by a
number genes that either alone or in combination may repre-
sent genetic risk constellations that influence the biological
reaction towards alcohol. Figure 2 depicts some of the possible
genetic candidates that are involved in the pathogenesis of
alcohol-related liver injury.
CASE–CONTROL STUDIES ON CANDIDATE
GENES IN ALD
In the following, case–control association studies aiming at
the identification of genetic risk markers for ALD will be
described and weighed regarding their strengths and weak-
nesses. The description of the studies is divided into sections
to pay tribute to the functional role of the tested genes in ALD.
Polymorphisms of genes involved in alcohol metabolism
After absorbtion, alcohol is degraded in the liver and other
tissues by alcohol dehydrogenase (ADH) in the cytosol and
cytochrome P450 2E1 in microsomes. Acetaldehyde is further
converted by aldehyde dehydrogenases (ALDH) to acetate
which, after release from the liver, is metabolized by heart
and skeletal muscle tissue.
Different classes of ADH isoenzymes are known and a
new nomenclature has been introduced recently (Duester
et al., 1999). As most studies have applied the old ADH
classification, it also will be used in this review. All ADHs
are dimeric zinc-containing enzymes classified according to
their metabolic properties and sequence similarities. Class I
ADH comprises isoenzymes with a, b, and g subunits coded
by corresponding gene loci termed ADH1, ADH2, and
ADH3 (Bosron et al., 1993). Among the human ADH gene
loci, two class I ADH genes are polymorphic with three alleles
existing for either ADH2 and ADH3 which reveal
substantially different enzymatic characteristics. ADH2
alleles are ADH2*1 found in Caucasians and ADH2*2
detectable in Asians which encode the low activity b1 and
the high activity b2 subunits, respectively. The resulting
dimeric isoenzymes have markedly different kcat values of
9.2 min–1 for b1b1 and 400 min–1 for b2b2, respectively.
The ADH3*1 and ADH3*2 alleles produce the g1 and g2
subunits, and the g1g1 isoenzyme is twice as active as the
g2g2 isoenzyme (kcat 87 min–1 vs 35 min–1). A recently
described ADH3*3 allele has not been enzymatically
charaterized (Osier et al., 2002).
According to the differences in the capacity to metabolize
alcohol to acetaldehyde, it has been speculated that individuals
with the more active ADH2*2 and ADH3*1 alleles are at
increased risk of developing alcohol-related organ damage
due to a higher acetaldehyde exposure (Couzigou et al.,
1994). The details of population-based case–control studies
that have tested a possible association of ADH variants with
ALD are summarized in Table 1. Studies were carried out in
Asian and Caucasian populations, but due to the fact that
the ADH2*2 allele is rare in Caucasians, most data regard-
ing this variant stem from investigations in Asians. However,
results are inconsistent. Earlier studies identified the
Pathophysiology Mediator Possible Candidate Genes
AcetaldehydeAlcohol toxicity ADH, ALDH
CYP2E1
ROS, EndotoxinsOxidative Stress CYP2E1, MnSOD, 
MPO, GSTs
Immune Response/
Inflammation
Cytokines/
Endotoxins
TNF α, INF γ, IL10, IL1β,
CD14
Collagen-Synthesis/
Degradation
TIMP‘s
Collagenases TIMP-1/-2, MMPs
Activation of Hepatic
Stellate Cells
TGFβ,  Angiotensinogen, 
Leptin, CTGF 
Profibrogenic Factors
Candidate Genes in the Progression of ALD
Fig. 2. Genetic susceptibility for the onset or progression of alcoholic liver disease could be related to genetic variation at any step of alcoholic liver damage
(e.g. alcohol metabolism, inflammation, and fibrogenesis).
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Table 1. Case–control studies on the association between polymorphisms of alcohol-metabolizing enzymes and ALD
Authors Tested gene(s) Sample size Definition of cases/controls
Functional
data Principle finding
(Couzigou
et al., 1990)
ADH2, ADH3 46 alcoholic cirrhosis
39 controls
Alcoholic cirrhosis: 100 g
alcohol/day for >5 years
None No association between either
ADH and ALD
Signs of portal
hypertension
(Day
et al., 1991)
ADH2, ADH3,
ALDH2
59 alcoholic cirrhosis
13 alcoholic
pancreatitis
Alcoholic cirrhotics: 80 g
alcohol/day
for >10 years
None ADH3*1 more frequent in
cirrhotics than in controls
(62.7 vs 55.1%, P < 0.05)
79 healthy Subjects Liver biopsy in all
cirrhotics
(Sherman
et al., 1993)
ADH2 38 ALD
23 healthy controls
Alcoholics: 80 g alcohol/day
for >2 years
None ADH2*B allele associated with
ALD
Liver biopsy in all ALD
(Chao
et al., 1994)
ADH2, ADH3,
ALDH2
27 alcoholic cirrhosis
23 viral cirrhosis
30 gastroduodenal
ulcers
Alcoholic cirrhotics: 80 g
alcohol/day for >10 years,
esophageal varices
Controls: ulcer patients without
alcohol consumption
None ADH2*2, ADH3*1 and
ALDH2*2 alleles significantly
less frequent in alcoholic
cirrhotics than in controls
(Yamauchi
et al., 1995a)
ADH2,
ALDH2,
CYP2E1
27 alcoholic fatty liver
7 non-specific
changes
46 alcoholic cirrhosis
60 healthy controls
Alcoholics: 120g alcohol/day
for >10 years
Liver histology in all patients
Controls: random
None ADH2*2/2 genotype associated
with alcoholic cirrhosis (OR 4.6;
no CI)
(Yamauchi
et al., 1995b)
ADH2 42 alcoholic cirrhosis
34 noncirrhotic
alcoholics
Alcoholics: 120g alcohol/day
for >10 years
Liver histology in all patients
None ADH2*2/2 genotype associated
with alcoholic cirrhosis
(Tanaka
et al., 1996)
ADH2,
ALDH2
31 ALD
90 alcohol addicts
66 healthy controls
Alcoholics: 80g alcohol/day
for >10 years
Liver histology in alcoholics
Controls: random
None ADH2*1/1 and ALDH2*1/1
more frequent in alcoholics/
ALD than in controls
(Tanaka
et al., 1997)
ADH2,
ALDH2,
CYP2E1
26 ALD
189 controls
Alcoholics: 80g alcohol/day
for >10 years
Liver histology in alcoholics
Controls: random
None ADH2*1/1, ALDH2*1/1 and
CYP2E1 c2 more frequent in
ALD than in controls
(Ceni
et al. 1997)
ADH2, ADH3,
ALDH2,
CYP2E1
100 alcoholics
(26 fatty liver,
29 steatofibrosis,
19 cirrhosis,
26 nonspecific
changes)
Alcoholics: 150g alcohol/day
or >10 years
Liver histology in alcoholics
None No association with severity
between ALD and any of the
tested polymorphisms
(Chao
et al., 1997)
ADH2,
ADH3,
ALDH2,
CYP2E1
75 alcoholic cirrhosis
48 acute pancreatitis
19 heavy drinkers
235 controls
Alcoholics: 60g alcohol/day
for >7 years
Cirrhosis: CHILD B and C,
esophageal varices
None ADH2*1 and ALDH2*1 more
frequent in alcoholic cirrhosis
than in controls plus pancreatitis
No difference for ADH2 and
CYP2E1
(Grove
et al., 1998)
ADH3,
CYP2E1
264 ALD
121 random controls
Alcoholics: 80g alcohol/day
for >10 years
Liver biopsy 228/264 patients
None No significant association
between ADH3 and CYP2E1,
and ALD
(Borras
et al., 2000)
ADH2, ADH3 180 alcoholic
cirrhosis
231 alcoholics
199 viral cirrhosis
224 healthy controls
Alcoholics: 100g (70g)
alcohol/day for >10 years
Non-alcoholics: <40g (20g)/day
None Linkage between ADH2*2 and
ADH3*1
ADH2*2 allele more frequent in
non-alcoholics but overall
frequency very low (0–4.8%)
(Monzoni
et al., 2001)
ADH2,
ADH3,
CYP2E1,
TNFa
158 alcoholics Alcoholics: 120g (60g)
alcohol/day
(questionnaire)
None ADH3*2 and CYP2E1 c2 allele
associated with severity of ALD
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Table 1. Continued
Authors Tested gene(s) Sample size Definition of cases/controls
Functional
data Principle finding
(Lee
et al., 2001)
ADH2, ADH3,
ALDH2,
CYP2E1
56 alcoholic
cirrhosis
52 alcoholics
without ALD
64 non-drinkers
Alcoholics: 80g alcohol/day
for >10 years
Cirrhosis: ascites, esophageal
varices, encephalopathy
None No association with severity
between alcoholic cirrhosis and
any of the tested Genes
(Frenzer
et al., 2002)
ADH2, ADH3,
ALDH2,
CYP2E1,
ApoE
GSTM1/T1,
57 alcoholic cirrhosis
71 alcoholic
pancreatitis
57 alcoholics
200 blood donors
Alcoholic cirrhosis:
biopsy-proven
or clinical evidence
None ADH3*2/2 genotype
more frequent in cirrhotics
than in blood donors
All cirrhotics had ADH2*1/1
(Vidal
et al., 2004)
ADH2, ADH3,
CYP2E1
99 alcoholic cirrhosis
118 ALD without
cirrhosis
47 alcoholics
255 non-alcoholics
(healthy, liver
disease, cirrhosis)
Alcoholics: 100 g
alcohol/day
for >10 years
Liver histology in
alcoholics
Non-alcoholics:
<20 g/day
None No association with severity
between ALD and any of the
tested Polymorphisms
(Tsutsumi
et al., 1994)
CYP2E1
(RsaI + PstI)
50 ALD
10 alcoholics without
ALD
34 Non-ALD
88 Non-liver disease
66 Healthy controls
Alcoholics: 80g
alcohol/day
for >5 years
Liver biopsy in all ALD
No characterization of
controls
Acetaminophen
elimination test
showed higher
activity in c2
homozygotes
Alcoholic cirrhotics had
higher rate of mutant c2
allele and c2
homozygosity
(Maezawa
et al., 1994)
CYP2E1
(RsaI + PstI)
20 alcoholic steatosis
62 alcoholic fibrosis/
cirrhosis
Alcoholics: 120 g
alcohol/day
for >10 years
None Genotype CYP2E1 c1/c1 more
frequent in advanced ALD
Liver biopsy in all ALD
(Chao
et al., 1995)
CYP2E1
(RsaI + PstI)
54 alcoholic cirrhosis
23 alcoholic
pancreatitis
33 non-liver disease
31 viral cirrhosis
100 healthy controls
Alcoholics: 80g
alcohol/day
for >8 years
All cirrhotics had
decompensated liver
disease
None No association of CYP2E1
allels with alcoholic cirrhosis
marked ethnic differences
between Asians and Caucasians/
African Americans
(Pirmohamed
et al., 1995)
CYP2E1
(RsaI + PstI)
95 ALD
58 alcoholics without
ALD
47 Non-ALD
100 healthy subjects
Alcoholics: 190g alcohol/day
(median) > 10 years
33% of ALD with biopsy
None c2 allele more frequent in ALD
(OR 4.5; CI 1.9-10.9)
(Carr
et al., 1995)
CYP2E1
(RsaI + PstI)
53 ALD (hepatitis
and cirrhosis)
21 alcoholics
without ALD
18 recovering
alcoholics
32 hospital staff
member
ALD: average intake 257g
alcohol for 27 years
Alcoholism: DSM II criteria
None No association of CYP2E1
alleles with alcoholic cirrhosis
(Ball
et al., 1995)
CYP2E1
(RsaI + PstI)
37 alcoholic
cirrhosis
24 Korsakoff‘s
syndrome
39 alcohol dependence
108 matched controls
Alcoholics: 80g alcohol/day
> 3 years
Liver biopsy in all ALD
None No association of CYP2E1
alleles with alcoholic cirrhosis
(Carr
et al., 1996)
CYP2E1
(RsaI + PstI)
Han Chinese:
30 alcoholic cirrhotics
46 alcoholics without ALD
100 random controls
Atayal Taiwanese:
34 alcoholics
35 normal controls
Alcoholics: 80g alcohol/day
> 10 years
Alcoholism: DSM II criteria
None No association of CYP2E1
alleles with alcoholic cirrhosis
and alcoholism
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ADH2*2 allele and genotype ADH2*2/2 as a risk factor for
ALD (Sherman et al., 1993; Chao et al., 1994; Yamauchi
et al., 1995a, 1995b), whereas subsequent investigations rather
found the allele ADH2*1 and genotype ADH2*1/1 to be
associated with ALD (Tanaka et al., 1996, Tanaka
et al., 1997; Chao et al., 1997; Frenzer et al., 2002). Among
the former it is noteworthy to mention, that Yamauchi et al.
(Yamauchi et al., 1995a, 1995b) were seemingly able to
publish the same data twice. While several investigators
reported associations between the ADH3*2 allele or
the ADH3*2/2 genotype, respectively, and ALD (Monzoni
et al., 2001; Frenzer et al., 2002), others suggested a role of
the high turnover allele ADH3*1 to confer risk to the
development of ALD (Day et al., 1991). However, a number
of studies found no association at all (Table 1). The true role
of ADH genotypes in the risk of ALD is difficult to define
since many of the published studies reveal important limita-
tions as regards the interpretability of the data. For example,
most studies reveal a very low sample size and, therefore, a
lack of statistical power likely hampers the significance of
the key finding. ‘Underpowered’ investigations are highly
susceptible towards chance observations which may explain
the discrepancies between many of the studies. Also, relatively
simple tests were used for statistical analyses, such as mere
counting of alleles and genotype frequencies, Student’s t-tests
and Fisher’s exact tests which are inappropriate for
determining the influence of certain factors in complex
settings. Only one study has applied a multiple logistic
Table 1. Continued
Authors Tested gene(s) Sample size Definition of cases/controls
Functional
data Principle finding
(Lucas
et al., 1996)
CYP2E1
(RsaI, DraI),
CYP1A1
(MspI)
202 alcoholics
without ALD
110 alcoholic
cirrhosis
62 esophageal cancer
96 UADT cancer
41 alcoholic disorders
Alcoholic cirrhosis confirmed
through biopsy
Assessment of alcohol
consumption not described
None No association of CYP2E1
alleles with alcoholic cirrhosis
DraI SNP more frequent among
alcoholics
(Agundez
et al., 1996)
CYP2E1
(RsaI)
58 alcoholic cirrhosis
137 normal controls
Alcoholics: 100g alcohol/day
for >10 years
None No association of CYP2E1
RsaI SNP with alcoholic
cirrhosis
(Savolainen
et al., 1997)
CYP2E1
(RsaI, PstI,
DraI, MspI)
Male autopsy cases
243 alcoholics
43 moderate drinkers
33 controls
Alcoholics: >80 g alcohol/day
Moderate drinkers: 10–80 g
Controls: 0–10 g
None No association of CYP2E1
alleles with ALD
RsaI + PstI very
infrequent
(Parsian
et al., 1998)
CYP2E1
(RsaI + PstI)
174 alcoholics
(43 cirrhosis)
89 controls
Alcoholics: Cloninger criteria
Liver histology in all cirrhotics
None No association of CYP2E1 alleles
with alcoholic cirrhosis or
alcoholism
(Rodrigo
et al., 1999)
CYP2E1
(PstI),
ADH2,
NAT2,
GSTM1
120 alcoholic
cirrhosis
30 alcoholics
without ALD
200 healthy controls
Alcoholics: 200g alcohol/day
> 20 years
None NAT2*5 allele (slow acetylator
status) decreased in alcoholic
cirrhotics
Other SNPs not related to
cirrhosis
(Itoga
et al., 1999)
9 exons and
exon- intron
junctions of
CYP2E1
44 ALD
96 alcoholics
without ALD
115 healthy controls
ALD: liver biopsy in all
ALD patients
Alcoholism: DSM III-R
Controls: non-drinking, light
consumption (22–44g/day >
5 years), moderate
consumption
(>66g/day > 5 years)
None No association between any
nucleotide replacement
and ALD
(Wong
et al., 2000)
CYP2E1
(RsaI, PstI,
TaqI)
61 ALD
46 HCC
375 healthy controls
Alcoholics: 60g alcohol/day for
>10 years
Liver biopsy in all ALD subjects
None No association between CYP2E1
RsaI and PstI SNPs and alcoholic
cirrhosis
TaqI SNP protective towards
alcoholc cirrhosis
(Pastorelli
et al., 2001)
CYP2E1
(RsaI +
PstI), DRD2
and SLC6A4
60 alcoholics
(18 cirrhosis)
64 healthy control
Alcohol quantification via
interview
None No association with severity
between ALD and any of the
tested polymorphisms
(Plee-Gautier
et al., 2001)
CYP2E1
(1C + 1D
alleles)
98 alcoholic cirrhosis
148 alcoholics
without ALD
103 random controls
Alcoholics: 80g alcohol/day for
more than ‘several’ years
Chlorzoxazone
test
No association between CYP2E1
1C and 1D alleles and alcoholic
cirrhosis
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regression analysis that takes numerous modifiers of disease
into account (Yamauchi et al., 1995b). Morerover, no study
presented in vitro or in vivo data supporting the functional
significance of the association and the hypothesis, such as
the testing for differences in acetaldehyde levels
in individuals with different genotypes. Overall, the available
data does not provide clear evidence that demonstrates a
contribution of ADH genotypes to the development of ALD.
A similar situation prevails with regard to genetic variants
of CYP2E1. In contrast to ADH and ALDH, CYP2E1 is an
inducible enzyme and its activity can increase up to 20-fold
following continuous alcohol consumption. Therefore,
functional polymorphisms are just one possible factor in the
individual variation of CYP2E1 activity. There are several
polymorphic loci within the human CYP2E1 gene of which
four are identifiable via RFLP (Hayashi et al., 1991). Two
mutations were found to be in linkage disequilibrium, giving
rise to the c1 and c2 allele (Watanabe et al., 1990).
The CYP2E1 c2 (mutated) allele is associated with an up to
10-fold higher gene transcription, protein level, and enzyme
activity than the c1 allele and could result in a higher exposure
of the liver towards acetaldehyde and ROS (Watanabe et al.,
1994). Therefore, CYP2E1 is an interesting candidate gene
in case–control association studies and published reports are
listed in Table 1. However, many of the limitations outlined
for ADH and ALDH genotype association studies also hold
true for studies investigating CYP2E1 SNPs including lack
of statistical power, insufficient characterization of cases and
controls, inappropriate statistical analysis, and lack of
functional data. Altogether, a significant contribution of
CYP2E1 variants to the emergence of ALD is unlikely.
While both ADH3 and CYP2E1 genotypes do not seem to
be a strong risk factor of progression of ALD, their significant
contribution to the development of HCC was suggested by two
reports which showed that individuals homozygous for the
alleles CYP2E1 c1 (Yu et al., 1995) and ADH3*1/ADH1C*1
(Homann et al., 2006) are at an increased risk to develop
hepatoma. In the latter study, 818 alcoholics either with or
without alcohol-related disorders including liver cirrhosis,
chronic pancreatitis, alcohol-related carcinoma of the
esophagus, head and neck, and liver (n = 86) were genotyped
for ADH3/ADH1C variants. The odds ratio for genotype
ADH3*1/1 regarding the development of HCC was 3.56
(CI 1.33–9.53) and multivariate analysis identified the
ADH3*1 allele and its homozygosity as independent risk
factors for HCC in heavy drinkers with preexisting cirrhosis.
Genetic polymorphisms of antioxidant enzymes
Numerous lines of evidence point to an important role of
oxidative stress in the pathogenesis of ALD. During alcohol
metabolism, ROS are generated as a result of the production
of NADH from the conversion of ethanol to acetaldehyde by
ADHs, and of NADPH from the metabolism of ethanol by
CYP2E1. ROS are highly reactive and can damage lipids,
proteins, and DNA (Arteel, 2003). Several enzymes exist
which counteract oxidative stress generated in ALD including
glutathione-S-transferases (GSTs) and superoxide dismutase.
GSTs are expressed in the liver and other organs and
comprise several gene subfamilies encoding sulphur-
containing enzymes which inactivate ROS and many toxic
and carcinogenic xenobiotics through conjugation with glu-
tathione (GSH) (Armstrong, 1997). GST isoenzymes reveal
profound differences in their structure and substrate specifi-
city and >30 polymorphic variants have been identified
(Hayes et al., 2005). Among these, polymorphisms of the a
(GSTA), m (GSTM), t (GSTT), and p (GSTP) classes have
been studied in patients with ALD and the major
characteristics of the published reports are outlined in Table 2.
Most case–control studies investigated the GSTM1 and
GSTT1 genes due to the existence of ‘null’ allelic variants
resulting from a partial deletion in either gene locus with
absence of enzyme activity. Consequently, a loss or deficiency
in GSTM1 and GSTT1 enzyme activity could potentially
increase the levels of toxic intermediates generated along
with chronic alcohol consumption. However, only few studies
have found an association between ‘null’ genotypes of
GSTM1 and GSTT1, and ALD (Groppi et al., 1991; Ladero
et al., 2005), while several reports showed no relation
(Savolainen et al., 1996; Rodrigo et al., 1999; Frenzer et al.,
2002; Burim et al., 2004; Hayes et al., 2005). However, in
the largest study, a significantly increased frequency of
GSTM1 ‘null’ genotype in heavy drinkers with advanced
ALD has been demonstrated (Savolainen et al., 1996). More-
over, a recent study from Spain showed an increased risk for
ALD in individuals with combined carriage of GSTM1 and
GSTT1 ‘null’ genotype (Ladero et al., 2005). Although
attractive, genetic polymorphisms of GST isoenzymes cannot
be considered as firmly established since findings are still
conflicting or have been generated in studies with an in-
sufficient design. Our own findings in a larger case–control
series indicate no risk of GSTP1 polymorphisms (Eurich, D.,
Friess, H., Hellerbrand, C., Homann, N., Kolb, A.,
O¨sterreicher, C. H., Patsenker, E. et al., unpublished data).
However, we have recently found genotype GSTP1 Val/Val
to be associated with the development of cirrhosis in patients
with hereditary hemochromatosis (Stickel et al., 2005). As in
ALD, oxidative stress plays an important role in the pathogen-
esis of hemochromatosis.
Hepatocyte mitochondria are prime targets of oxidative
stress generated in chronic alcoholism and alterations of
mitochondrial function and structure, such as the breakdown
of mitochondrial membrane potential, have been recognized
as key events in the onset of alcohol-driven apoptosis
(Adachi and Ishii, 2002). The ability to resist oxidative pres-
sure largely depends on the mitochondrial GSH content and
antioxidant mitochondrial enzymes. Mitochondria-derived
ROS are detoxified to hydrogen peroxide and water by the
successive action of manganese superoxide dismutase
(MnSOD) and GSH peroxidase, respectively (Wallace,
1999). MnSOD is synthesized with a cleavable N-terminal
mitochondrial target sequence that enables its transport into
mitochondria (Shimoda-Matsubayashi et al., 1996). A SNP
within codon 16 of the precursor protein leads to either alanine
(Ala) or valine (Val) at amino acid position –9 of the target
sequence resulting in enhanced translocation into mitochon-
dria and higher concentration of active MnSOD in case of
the Ala-sequence (Sutton et al., 2003). Table 2 summerizes
case–control studies that investigated MnSOD variants.
Degoul et al. (2001) have genotyped 71 patients with ALD
stratified according to the degree of liver damage and have
found that the Ala/Ala genotype occurs more frequently in
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Table 2. Case–control studies on the association between polymorphisms of antioxidant enzymes and ALD
Authors Tested gene(s) Sample size Definition of cases/controls
Functional
data Principle finding
(Groppi
et al., 1991)
GSTM1 45 alcoholic cirrhosis
45 healthy controls
Cirrhotics: >100 g alcohol/day
for >5 years
Presence of ascites, varices
None No relationship between
alcoholic cirrhosis and
GSTM1 genotypes
(Savolainen
et al., 1996)
GSTM1 313 alcoholics
43 moderate drinkers
33 control subjects
Alcoholics: >80 g alcohol/day
Moderate drinkers:
10–80 g
Controls: 0–10 g
None GSTM1 ‘null’ genotype more
frequent among ALD with
advanced fibrosis (OR 2.3;
CI 1.11-4.76)
(Rodrigo
et al., 1999)
GSTM1,
CYP2E1
(PstI), ADH2,
NAT2,
120 alcoholic
cirrhosis
30 alcoholics
without ALD
200 healthy controls
Alcoholics: 200 g alcohol/day
for >20 years
None GSTM1 polymorphism not
related to cirrhosis
(Frenzer
et al., 2002)
GSTM1/T1,
ADH2,
ADH3,
ALDH2,
CYP2E1,
ApoE
57 alcoholic cirrhosis
71 alcoholic
pancreatitis
57 alcoholics
200 blood donors
Alcoholic cirrhosis:
biopsy-proven or clinical
evidence
None No association between
alcohol-related disorders and
GST genotypes
(Burim
et al., 2004)
GSTM1, T1,
P1, CYP2E1,
CYP1A1
65 alcoholic cirrhotics
14 alcoholic
pancreatitis
41 alcoholics
221 non-alcoholic
controls
Alcoholics: >40g alcohol/day
obtained from case records
Mixed ethnicity
None GSTs not associated with any of
the endpoints
CYP1A1 associated with
cirrhosis (OR 5.33;
CI 1.23–23.14)
(Brind
et al., 2004)
GSTM1, M3,
P1, T1, A1
Unclear number of
healthy controls,
alcoholics without
ALD, and ALD
patients
Alcoholics: different definitions
in three centers
None No association between ALD and
any of the tested SNPs
(Ladero
et al., 2005)
GSTM1, T1 153 ALD
241 random controls
Alcoholics: 150 g alcohol/day
(median) for >10 years
Cirrhosis: clinical and imaging
evidence of portal hypertension
None GSTT1 ‘null’
genotype associated with ALD
(OR 1.67; CI 1.03–2.71)
Carriers of GSTT1 and M1
‘null’ genotypes are
at increased risk for ALD
(OR 4.3; CI 1.89–9.97)
(Degoul
et al., 2001)
MnSOD 71 ALD
79 blood donors
Average alcohol intake 151 g
(±98)/day for 18 ± 6 years
Liver biopsy in all ALD patients
None Rate of MnSOD Ala homozygos
ity increased significantly with
severity of ALD (RR of cirrhosis
for Ala/Ala 9.6; CI 2.6–35.4)
(Stewart
et al., 2002)
MnSOD 281 advanced ALD
218 alcoholics
without ALD
244 healthy controls
Alcoholics: 80g alcohol/day
for >10 years
ALD: clinical and biochemical
evidence, imaging
Controls: alcohol <21 U (men),
<15 U (women)
Circulating
antibodies raised
against markers
of oxidative
stress
No difference in MnSOD geno
type and allele frequencies
between groups.
Serum markers of oxidative stress
similar in different genotypes
(Brind
et al., 2003)
MnSOD 357 ALD
93 alcoholics
without ALD
474 non-drinking
controls
Alcoholics: different definitions
in three centers
None No difference in MnSOD geno
type and allele frequencies
between groups
(Nahon
et al., 2005)
MnSOD Longitudinal study in
264 alcohol
cirrhotics
Alcoholic cirrhosis: liver biopsy,
for >80 g alcohol/day,
alphafetoprotein
<50 ng/ml
None RR for HCC with 1 Ala allele
4.59 (CI 1.61–13.06)
RR for death due to cirrhosis with
1 Ala allele 2.49 (CI 1.36–4.57)
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patients with severe ALD. They assessed an OR of 9.6 (CI
2.6–35.4) for genotype MnSOD Ala/Ala for the presence of
cirrhosis. However, the study included only 13 cirrhotic
patients. Although the authors did not provide a power calcu-
lation, there is an obvious lack of statistical power due to a
small sample size. The same group later presented data from
a longitudinal study suggesting that the presence of at least
one Ala MnSOD allele increases the risk for developing
cirrhosis in French subjects and, furthermore, with the
development of HCC and death due to cirrhosis (Nahon
et al., 2005). However, case–control studies from other
researchers with larger numbers of patients and controls could
not confirm these findings (Stewart et al., 2002; Brind et al.,
2003).
Polymorphic genes coding for cytokines involved in ALD
Compelling evidence points to an important role of the
immune system in mediating alcoholic liver injury. The innate
immune response acts as the first line of nonspecific defense
against exogenous pathogens such as ROS, lipid peroxides,
and endotoxins/lipopolysaccharides derived from the outer
cell membrane wall of gram negative bacteria in the intestine
which activate immune effector cells. Particularly, Kupffer
cells play an important role and experimental inhibition of
Kupffer cells prevents an array of hepatic reactions in
response to ethanol including the elevation of serum
transaminases, steatosis, inflammation, and necrosis (Hines
and Wheeler, 2004). Numerous experimental studies found
that Kupffer cells are stimulated by various triggers to produce
a number of cytokines including tumor necrosis factor a
(TNFa), a proinflammatory cytokine known to potentially
cause hepatocyte death. Apart from TNFa, several other
cytokines including interleukins, interferons, chemokines,
and certain growth factors regulate hepatic inflammation,
apoptotic and necrotic cell death, cholestasis, and fibrosis
(Tilg and Diehl, 2000). For several genes that code for proteins
involved in these processes, polymorphisms with functional
implications have been detected that render these variants
interesting candidates for case–control association studies.
Excess TNF-a production is a typical feature of ALD. The
biological response is dependent on the level of TNF-a
the liver is exposed to and may result in increased hepatocyte
proliferation, activation of cell survival factors such as
upregulation of MnSOD and bcl-xL, or cell death through
initiation of apoptosis or necrosis. Therefore, polymorphic
variation of the TNF-a gene leading to variable TNF-a levels
may influence TNF-a-dependent inflammation following
alcohol intake. In fact, two SNPs at position –308 (G!A)
and –238 (G!A), respectively, of the TNF-a gene are associ-
ated with increased TNF-a expression thereby possibly influ-
encing the progression of ALD (Wilson et al., 1993;
D’Alfonso and Richiardi, 1994). Grove and co-workers
(Grove et al., 1997) were the first to study these two TNF-a
polymorphism in a cohort of patients with ALD. While the
distribution of the polymorphism at position –308 was not dif-
ferent between the cases and controls, an excess of the rare
TNFA-A allele at position –238 was found in patients with
ALD. The OR for this variant vs non-diseased patients was
3.5 (0.4–28) with regard to cirrhosis and 4 (1.2–14) for alco-
holic steatohepatitis. All patients had biopsy-proven ALD
and the distribution of genotypes was in Hardy–Weinberg
equilibrium in all groups. However, the authors did not
provide evidence that the tested polymorphisms resulted in
differences in TNF-a serum levels, neither did they show
SNP-dependent variation in hepatic TNF-a expression.
Two subsequent cohort studies also tested TNF-a variants
but found no association (Bathgate et al., 2000; Ladero et al.,
2002). However, one study testing the TNF-a –308 SNP
investigated only 25 patients with ALD and, therefore, could
have missed a relationship due to low sample size (Bathgate
et al., 2000). The other study included a larger number of
ALD patients but was carried out in Spain, so ethnic differ-
ences may have contributed to the discrepancy (Ladero et al.,
2002). The latter two studies also included several poly-
morphisms in the interleukin-10 (IL-10) gene which alter
gene transcription and IL-10 serum concentrations. IL-10 has
emerged as an important inhibitor of inflammatory responses
such as the downregulation of proinflammatory cytokines
including IL-1, TNF-a, IL-6, IL-8, and IL-12. Moreover,
IL-10 was shown to upregulate the expression of the IL-1R
antagonist, to inhibit collagen gene transcription, and to
increase collagenase expression in HSC (Wang et al., 1998).
However, no association was found in contrast to a previous
report in 287 patients with biopsy-proven ALD in which the
possession of the A allele in the IL-10 promoter was
associated with an increased risk of advanced ALD (Grove
et al., 2000).
Two reports are available on the association of a
polymorphism in the interleukin-1 receptor antagonist
(IL-1Ra) gene with ALD (Takamatsu et al., 1998; Pastor
et al., 2000). IL-1Ra is a potent antiinflammatory cytokine
that can inhibit immune-mediated inflammatory reactions.
IL-1Ra relates to IL1 which binds to its corresponding
receptor IL-1 (IL-1R). A variable nucleotide tandem repeat
polymorphism resulting in different allele sizes due to variable
numbers of repeats (A1: 4 repeats; A2: 2 repeats; A3: 5
repeats; A4: 3 repeats) was shown to alter IL-1Ra expression
in monocytes in vitro (Danis et al., 1995). One study included
Spanish alcoholics with alcohol addiction, significant alcohol
abuse, and alcoholic cirrhosis, respectively (Pastor et al.,
2000). While the presence of the A1 allele increased the risk
for alcoholism, no relationship with ALD was detected. In
the Japanese study, genotype and allele distributions differed
from that in Caucasians and heterozygosity for the A1 allele
was more frequent in alcoholics with fibrosis than in those
without (Takamatsu et al., 1998). However, this difference
did not reach statistical significance. Owing to the low number
of cases, the findings of the latter study are highly suspicious
of being chance observations which particularly occur in
genotypes with low frequencies (Day, 2003).
In addition, one study each was performed to investigate
a possible relationship between poylmorphisms of inter-
leukin-1b (IL-1b), a promoter polymorphism of the
CD14 endotoxin receptor, and the cytotoxic T-lymphocyte
antigen-4 gene (CTLA-4), and ALD. The details of studies
on polymorphic variation of cytokine genes in the develop-
ment of alcoholic hepatitis and cirrhosis are outlined in
Table 3. All three reports found associations between certain
genotypes and the development of alcoholic cirrhosis; how-
ever, no other study has so far repeated, let alone confirmed
these findings.
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Genetic variants of genes relevant for fibrogenesis
and fibrolysis
Genes that govern the production and degradation of fibrous
tissue are interesting with regard to many etiologies of chronic
liver disease since the formation of fibrosis in different disease
entities share many similarities (Friedman, 2000). These genes
could represent genetic markers of progression rather than of
the susceptibility towards a certain disease trigger since
fibrosis develops with a long latency that is unlikely to influ-
ence behavioral aspects of alcoholism. Consequently, genes
that were identified to confer risk to advanced liver damage
in one form of chronic liver disease is likely to be involved
in another etiology as well. Accordingly, several candidate
genes that are involved in connective tissue turnover have
Table 3. Case–control studies on the association between polymorphisms of cytokines and immune factors, and ALD
Authors Tested gene(s) Sample size Definition of cases/controls
Functional
data Principle finding
(Grove
et al., 1997)
TNFa 150 ALD (cirrhosis, ASH)
145 controls
Alcoholics: 80 g alcohol/day
>10 years
Liver biopsy in all ALD
None –238 TNF-a G/A genotype
associated with cirrhosis (OR
3.5; CI 0.4–28) and ASH (OR 4;
CI 1.2–14)
(Takamatsu
et al., 1998)
IL-1R
antagonist
46 alcoholic cirrhosis
21 alcoholic fibrosis
35 alcoholics without ALD
46 healthy subjects
Alcoholics: 120g
alcohol/day > 10 years
Liver biopsy in all ALD
None IL-1Ra A1 heterozygotes more
frequent in fibrosis/cirrhosis
Cumulative alcohol intake lower in
A1 carriers with alcoholic fibrosis
(Grove
et al., 2000)
IL-10 287 advanced ALD
107 NALD
227 healthy subjects
Alcoholics: 80 g alcohol/day
>10 years
ALD: clinical and
biochemical evidence,
imaging, biopsy
None Carriage of A allele (–627) of IL-10
promoter associated with advanced
ALD (OR 2.04; CI 1.42–2.92)
(Bathgate
et al., 2000)
TNFa, IL-10,
TGFb1
25 ALD
113 non-alcoholic end-stage
liver disease (viral,
cholestatic, autoimmune,
acute liver failure)
All patients transplant
recipients
Alcohol consumption
not detailed
None None of the tested genotypes
associated with ALD
(Ladero
et al., 2002)
TNFa, IL-10 147 advanced ALD
355 control subjects
Alcoholics: 150 g alcohol/day
(mean) >10 years
ALD: clinical evidence,
imaging results, endoscopy,
biopsy (n = 12)
None Single SNPs not related to ALD
Excess of G11-GCC haplotype in
ALD(OR 2.08; CI 1.31-3.31)
(Takamatsu
et al., 2000)
IL-1b 142 ALD (steatofibrosis,
cirrhosis, alcoholic hepatitis)
Alcoholics: 120 g alcohol/day
for >10 years
Liver biopsy in all ALD
None Carriers of –511 IL-1b allele 2 more
frequent among alcoholic cirrhotics
(OR 2.3; CI 1.1–4.8)
Haplotype IL-1b –511 allele 2/+3953
allele 1 associated with alcoholic
cirrhosis
(Ja¨rvelainen
et al., 2001)
CD14-
Endotoxin
receptor
48 alcoholic cirrhosis
39 alcoholic hepatitis
59 alcoholic fibrosis
108 steatosis
178 normal liver
Alcoholics: 40g alcohol/day
for 24.9 (±10.8) years
ALD: autopsy
None T allele of CD14-Endotoxin receptor
associated with alcoholic hepatitis
(OR 2.48; CI 1.17–5.24) and
alcoholic cirrhosis (OR 3.45;
CI 1.49–7.99)
(Valenti
et al., 2004)
CTLA-4 183 ALD (cirrhosis, fibrosis,
steatosis)
115 chronic hepatitis C
102 Non-alcoholic fatty liver
disease
Alcoholics: 60 g (men)/ 40 g
(women) alcohol/day for >5
years
Alcoholic cirrhosis assessed
with biopsy in 128/183
None Genotype CTLA-4 G/G associated
with ALD (OR 3.5; CI 1.1–11)
(Pastor
et al., 2000)
IL-1R
antagonist
30 alcoholic cirrhosis
30 alcohol abusers
30 alcohol dependent men
Alcoholics: 100g alcohol/day
for >5 years
Alcoholic cirrhosis: biopsy
(n = 24), biochemical
evidence (n = 6)
None Presence of the A1 IL-1R antagonist
allele associated with alcoholism
but not with alcoholic cirrhosis
(Oliver
et al., 2005)
TGFb1 165 advanced ALD
185 controls
Alcoholics: 167 g alcohol/day
(mean) >10 years
None No association between tested SNP
and ALD
ALD: clinical evidence,
imaging results, endoscopy,
biopsy (n = 16)
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been tested in other diseases, such as TGFb1 in chronic hepati-
tis C (Powell et al., 2000) and hemochromatosis (O¨sterreicher
et al., 2005), MMPs in primary sclerosing cholangitis
(Satsangi et al., 2001), and TIMPs in the development of
asthma and arterial aneurysms (Krex et al., 2003; Lose
et al., 2005).
With regard to ALD, only data from studies on the role
of TGF-b1 polymorphisms are available so far (Table 3).
Two studies have analyzed several TGF-b1 polymorphisms
which lead to elevated TGF-b1 expression in the setting of
ALD, neither found an association with alcoholic cirrhosis
(Bathgate et al., 2000; Oliver et al., 2005). Our own data on
a polymorphism at codon 25 of the signal sequence
(Arg!Pro) within the TGFb1 gene resulting in higher
TGFb1 levels showed no difference in a cohort of
153 alcoholic cirrhosis compared with a cohort of 118
matched heavy drinkers without liver damage (Eurich, D.,
Friess, H., Hellerbrand, C., Homann, N., Kolb, A.,
O¨sterreicher, C. H., Patsenker, E. et al., unpublished data).
With regard to the progression of fibrosis, MMPs qualify as
ideal candidates since their function is closely linked to the
accumulation of ECM. Among several MMPs that are
expressed in the liver, MMP-3 (stromelysin) is crucial because
of its capacity to degrade a broad spectrum of ECM molecules
and to activate other MMPs. The presence of 5 adenosines
(5A) instead of 6 adenosines (6A) at bp –1171 results in
increased MMP-3 activity (Ye et al., 1996). As mentioned
above, a recent study found an association between genotype
MMP-3 5A/5A and the progression of liver damage in patients
with primary sclerosing cholangitis (Satsangi et al., 2001), but
its role in ALD is unknown. In a recent study from our own
group, MMP-3 5A/5A genotype was found more frequently
in alcoholic cirrhotics than in those without (30.1 vs 15.3%,
P = 0.017), and multivariate analysis identified age and
genotype MMP-3 5A/5A as independent risk factors for
alcoholic cirrhosis (Stickel et al., manuscript in revision).
The adjusted odds ratio of genotype MMP-3 5A/5A for
the development of cirrhosis was 1.52 (95% CI 1.108–2.086,
P = 0.010). Notably, RT–PCR revealed significantly higher
MMP-3 transcription in individuals with MMP-3 5A/5A
genotype compared with the MMP-3 5A/6A (6A/6A) variant.
However, whether the MMP-3 5A/5A genotype represents the
first fibrosis-associated genetic risk factor for the progression
of ALD remains to be confirmed in an independent cohort of
alcoholic cirrhotics.
DESIGN OF GENETIC ASSOCIATION STUDIES
Many published genotype–phenotype association studies
were carried out based on exciting hypotheses but collected
questionable genetic data since important requirements to
design and statistical interpretation were not met. Con-
sequently, not only results were published that could not be
reproduced due to lack of a true association with the studied
disease, but also some investigations may have even missed
an association because of an insufficient approach. Frequently
encountered problems of previous case–control association
studies in many diseases include the lack of statistical power
due to small sample size (Ioannidis et al., 2003), population
stratification (Cardon and Bell, 2001), ethnic heterogeneity
(Deng, 2001), deviation form Hardy–Weinberg equilibrium
due to errors in patient and control selection or genotyping,
and lack of control for confounding factors (Colhoun
et al., 2003). Consequently, replication validity of genetic
association studies has been unsatisfactory because results of
the first study rarely correlated with subsequent findings.
This discrepancy is more likely to occur as more studies are
performed on a potential association and when the sample
size of the first study has been low (Ioannidis et al., 2001).
Notably, ‘index’ studies on a genotype–phenotype association
are often published in prestigious journals that yield high
impact factors, whereas subsequent research with often better
design face problems to get accepted at all, or appear in jour-
nals with lower average impact factors. The same accounts for
the calculated odds ratios for a given association: while the
first study indicated impressive estimates of predisposition
against or protection from a certain disease, subsequent data
tended to show much less pronounced relationships or even
the opposite (Ioannidis et al., 2001).
In order to avoid these mistakes and to prevent much energy
and financial resources from being wasted on time-consuming
and, lastly, unreproducible efforts, some recommendations are
proposed for the design of genetic case–control association
studies (Table 4).
CONCLUSION
Agreement exists that the manifestation of ALD is partly
determined by genetic factors and substantial efforts have
Table 4. Recommendations for design and data analysis of genetic
case–control associaiton studies
Recommendation
Candidate gene Define a convincing rationale for the selection of the
studied gene(s)
Inlude several genes with related roles in disease
pathogenesis or common haplotypes with which the
gene of interest cosegregates
Validate reliability of genotyping procedure by
repeated blinded testing
Genetic variant Ensure functional implication of the genetic variant
and make sure it leads to a plausible hypothesis
Refer to published functional evidence of the studied
polymorphisms, or, if not available, include own in
vitro or in vivo data to support association with
functional differences
Selection of cases
and controls
Define cases and controls according to standardized
criteria that allow correction for covariates of the
disease (exposure to trigger, comorbidities).
Consider important demographic factors (ethnicity,
age, gender)
Recruit patients and controls prospectively
Attempt to confirm key finding in an independent
cohort of cases and controls recruited along the
same strategy
Data analysis Perform power calculation prior to recruitment to
avoid ‘underpowered’ studies
Evaluate data by applying a multivariate logistic
regression analysis that corrects for potential
covariates and minimizes confounding effects
Check whether the observed association is in
agreement with the function of the genetic variant
and whether there is a dose-response effect
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been made to identify such genetic modifiers, mostly by
means of genetic case–control association studies. SNPs of
genes that code for proteins that play a role in the pathogenesis
of ALD were tested. So far, results are conflicting and initial
euphoria over seemingly identified genetic markers has faded
since many results could not be reproduced. Therefore, future
studies have to adopt certain criteria that assure statistical
power via large-scale multicenter cooperations, functional
relevance of the tested genes/haplotypes, and consider
functional proteomics and genomics. Bearing this in mind,
research efforts will contribute to better disease management
and patients’ benefit.
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